For the quarter ending 2026-01-31.
| Income Statement | 2026-01-31 | 2025-10-31 | 2025-07-31 | |
|---|---|---|---|---|
| Research and development | 1,278,629 | 176,283 | 1,740,867 | |
| General and administrative | 919,025 | 821,826 | 959,334 | |
| Total operating expenses | 2,197,654 | 998,109 | 2,700,201 | |
| Loss from operations | -2,197,654 | -998,109 | -2,700,201 | |
| Interest expense | 1,337 | 2,649 | 2,483 | |
| Total other expense, net | -1,337 | -2,649 | -2,483 | |
| Net loss | -2,198,991 | -1,000,758 | -2,702,684 | |
| Net loss available to common shares | -2,198,991 | -1,000,758 | - | |
| Basic EPS | -0.58 | -0.3 | -1.28 | |
| Diluted EPS | -0.58 | -0.3 | -1.28 | |
| Basic Average Shares | 3,804,741 | 3,380,968 | 2,106,036 | |
| Diluted Average Shares | 3,804,741 | 3,380,968 | 2,106,036 | |
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc. (ALZN)